Entering text into the input field will update the search result below

Switzerland approves CNS Pharma's berubicin study in brain cancer

Brain Tumor

peterschreiber.media/iStock via Getty Images

  • CNS Pharmaceuticals (NASDAQ:CNSP) has received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, for its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), a type of brain cancer.

Recommended For You

More Trending News

About CNSP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CNSP--
CNS Pharmaceuticals, Inc.